Recipient: Helmholtz-Zentrum für Infektionsforschung GmbH (Helmholtz Centre for Infection Research)
Funding: GO-Bio initial conceptual phase 4 (01/10/2023 to 30/09/2024, EUR 96,766.00)

Project description:

One of the biggest challenges in drug development is the selection of drug dose and dosing regimens. New drug candidates must demonstrate high efficacy and safety. Even in successful clinical trials, dosages and therapies should be chosen to maximise the efficacy of a drug and minimise side effects. Within the framework of the MISOD project, in-silico methods and mathematical modelling will be combined to calculate an optimisation of drug dosage. The project builds on existing results on dosage optimisation of the tobramycin and colistin antibiotics for the treatment of Pseudomonas aeruginosa in in-vitro biofilms. The developed methodology is intended to help pharmaceutical and biotech companies as well as contract research organisations with future drug development. In the upcoming exploratory phase a customer-oriented online platform is to be developed. To this end a market and freedom-to-operate analysis will be carried out and a development plan for the subsequent feasibility phase will be drawn up.